Navigation Links
Abaxis, Inc. to Present at the Citi 2012 Global Health Care Conference and RBC Capital Markets' 2012 Healthcare Conference
Date:2/24/2012

UNION CITY, Calif., Feb. 24, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer,  will present at the Citi 2012 Global Health Care Conference and the RBC Capital Markets' 2012 Healthcare Conference.

The Citi conference presentation is scheduled for Monday, February 27, 2012 at 11:30 a.m. ET. The Citi conference will be held at the Waldorf Astoria Hotel in New York City.

The RBC conference presentation is scheduled for Tuesday, February 28, 2012 at 11:30 a.m. ET. The RBC conference will be held at the New York Palace Hotel in New York City.

A live webcast of the RBC 2012 Healthcare Conference presentation will be available to all interested parties at
http://www.wsw.com/webcast/rbc141/abax.

About Abaxis
Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).

The audio webcast will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements. Contact:

Clint Severson

Lytham Partners, LLC 

Chief Executive Officer

Joe Dorame, Joe Diaz & Robert Blum 

ABAXIS, Inc.

602-889-9700 

510-675-6500

  


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Abaxis, Inc. to Present at Stephens, Inc. 2011 Fall Investment Conference
3. Abaxis, Inc. to Present at Sidoti & Companys New York II Emerging Growth Institutional Investor Forum
4. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
5. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
6. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Abaxis, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. Abaxis, Inc. to Present at RBC Capital Markets Healthcare Conference
9. Abaxis, Inc. to Present at Stephens Fall Investment Conference
10. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
11. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... May 26, 2016- In search of the K. Warriors, Shaolin ... of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West ... and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of ... not surprising that bariatric surgery has received increased attention in recent years, as an ... when it comes to weight loss, most people are familiar with the basic requirements ...
(Date:5/27/2016)... Gilsum, New Hampshire (PRWEB) , ... May 27, 2016 , ... ... natural skin care products, announced today that it has been recognized as one of ... men entering parenthood. Badger was named as one of nine small businesses providing progressive ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... This campaign ... a stroke, which we as a society can control and change. , As nearly ... nearly every 40 seconds within the United States. Plus, with an estimated 129,000 of ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active duty ... that Coolsculpting is being used for for more than just cosmetic purposes. ... prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is used ...
Breaking Medicine News(10 mins):